Biotech's Next Big Thing: Biogen
Biogen Idec's earnings will be the next big thing in biotech says TheStreet Sr. Columnist Adam Feuerstein.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.
